(1S,4R,6S,14S,18R)-(18-amino-4-((cyclopropanesulfonyl)aminocarbonyl)-2,15-dioxo-3,16-diazatricyclo[14.3.0.0^4,6]nonadec-7-en-14-yl)carbamic acid tert-butyl ester

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (1S,4R,6S,14S,18R)-(18-amino-4-((cyclopropanesulfonyl)aminocarbonyl)-2,15-dioxo-3,16-diazatricyclo[14.3.0.0^4,6]nonadec-7-en-14-yl)carbamic acid tert-butyl ester
• 英文别名: (1S,4R,6S,14S,18R)-(18-amino-4-cyclopropanesulfonylaminocarbonyl-2,15-dioxo-3,16-diaza-tricyclo[14.3.0.04,6]nonadec-7-en-14-yl)-carbamic acid tert-butyl ester；tert-butyl N-[(1S,4R,6S,14S,18R)-18-amino-4-(cyclopropylsulfonylcarbamoyl)-2,15-dioxo-3,16-diazatricyclo[14.3.0.04,6]nonadec-7-en-14-yl]carbamate
• 化学式: C₂₆H₄₁N₅O₇S
• 分子量: 567.707
• InChiKey: HJESIZQCGVUYRV-SSIIITMNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  39
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  185
• 氢给体数：
  4
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  3-氯苯并ób]噻酚-2-羰酰氯 、 (1S,4R,6S,14S,18R)-(18-amino-4-((cyclopropanesulfonyl)aminocarbonyl)-2,15-dioxo-3,16-diazatricyclo[14.3.0.0^4,6]nonadec-7-en-14-yl)carbamic acid tert-butyl ester 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 (1S,4R,6S,14S,18R)-{18-[(3-chlorobenzo[b]thiophene-2-carbonyl)amino]-4-((cyclopropanesulfonyl)aminocarbonyl)-2,15-dioxo-3,16-diazatricyclo[14.3.0.0^4,6]nonadec-7-en-14-yl}carbamic acid tert-butyl ester
  参考文献：
  名称：

  Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease

  摘要：

  HCV serine protease NS3 represents an attractive drug target because it is not only essential for viral replication but also implicated in the viral evasion of the host immune response pathway through direct cleavage of key proteins in the human innate immune system. Through structure-based drug design and optimization, macrocyclic peptidomimetic molecules bearing both a lipophilic P2 isoindoline carbamate and a Pl/P1' acylsulfonamide/acylsulfamide carboxylic acid bioisostere were prepared that possessed subnanomolar potency against the NS3 protease in a subgenomic replicon-based cellular assay (Huh-7). Danoprevir (compound 49) was selected as the clinical development candidate for its favorable potency profile across multiple HCV genotypes and key mutant strains and for its good in vitro ADME profiles and in vivo target tissue (liver) exposures across multiple animal species. X-ray crystallographic studies elucidated several key features in the binding of danoprevir to HCV NS3 protease and proved invaluable to our iterative structure-based design strategy.

  DOI：

  10.1021/jm400164c
• 作为产物：
  描述：

  (1R,2S)-REL-1-[[(1,1-二甲基乙氧基)羰基]氨基]-2-乙烯基-环丙羧酸乙酯 在 盐酸 、 二氯(邻异丙氧基苯基亚甲基)(三环己基膦)钌 、 四丁基氟化铵 、 水 、 N,N-二异丙基乙胺 、 N,N'-羰基二咪唑 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 、 1,2-二氯乙烷 为溶剂， 反应 39.0h， 生成 (1S,4R,6S,14S,18R)-(18-amino-4-((cyclopropanesulfonyl)aminocarbonyl)-2,15-dioxo-3,16-diazatricyclo[14.3.0.0^4,6]nonadec-7-en-14-yl)carbamic acid tert-butyl ester
  参考文献：
  名称：

  Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease

  摘要：

  HCV serine protease NS3 represents an attractive drug target because it is not only essential for viral replication but also implicated in the viral evasion of the host immune response pathway through direct cleavage of key proteins in the human innate immune system. Through structure-based drug design and optimization, macrocyclic peptidomimetic molecules bearing both a lipophilic P2 isoindoline carbamate and a Pl/P1' acylsulfonamide/acylsulfamide carboxylic acid bioisostere were prepared that possessed subnanomolar potency against the NS3 protease in a subgenomic replicon-based cellular assay (Huh-7). Danoprevir (compound 49) was selected as the clinical development candidate for its favorable potency profile across multiple HCV genotypes and key mutant strains and for its good in vitro ADME profiles and in vivo target tissue (liver) exposures across multiple animal species. X-ray crystallographic studies elucidated several key features in the binding of danoprevir to HCV NS3 protease and proved invaluable to our iterative structure-based design strategy.

  DOI：

  10.1021/jm400164c

文献信息

• Macrocyclic compounds as inhibitors of viral replication
  申请人：Blatt M. Lawrence

  公开号：US20050267018A1

  公开（公告）日：2005-12-01

  The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  本实施例提供了一般公式I-XIX的化合物，以及包括药物组合物在内的组合物，其中包括一种主体化合物。本实施例还提供了治疗方法，包括治疗黄热病病毒感染的方法，包括丙型肝炎病毒感染的方法以及治疗肝纤维化的方法，这些方法通常涉及向需要治疗的个体施用一种主体化合物或组合物的有效量。
• MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION
  申请人：BLATT LAWRENCE M.

  公开号：US20090286843A1

  公开（公告）日：2009-11-19

  The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  该实施例提供了一般式I-XIX的化合物，以及包括药物组合物在内的组合物。该实施例还提供了治疗方法，包括治疗黄热病毒感染的方法，包括丙型肝炎病毒感染的方法和治疗肝纤维化的方法，通常涉及向需要治疗的个体施用所述化合物或组合物的有效量。
• Discovery of Danoprevir (ITMN-191/R7227), a Highly Selective and Potent Inhibitor of Hepatitis C Virus (HCV) NS3/4A Protease
  作者：Yutong Jiang、Steven W. Andrews、Kevin R. Condroski、Brad Buckman、Vlad Serebryany、Steve Wenglowsky、April L. Kennedy、Machender R. Madduru、Bin Wang、Michael Lyon、George A. Doherty、Benjamin T. Woodard、Christine Lemieux、Mary Geck Do、Hailong Zhang、Joshua Ballard、Guy Vigers、Barbra J. Brandhuber、Peter Stengel、John A. Josey、Leonid Beigelman、Lawrence Blatt、Scott D. Seiwert

  DOI：10.1021/jm400164c

  日期：2014.3.13

  HCV serine protease NS3 represents an attractive drug target because it is not only essential for viral replication but also implicated in the viral evasion of the host immune response pathway through direct cleavage of key proteins in the human innate immune system. Through structure-based drug design and optimization, macrocyclic peptidomimetic molecules bearing both a lipophilic P2 isoindoline carbamate and a Pl/P1' acylsulfonamide/acylsulfamide carboxylic acid bioisostere were prepared that possessed subnanomolar potency against the NS3 protease in a subgenomic replicon-based cellular assay (Huh-7). Danoprevir (compound 49) was selected as the clinical development candidate for its favorable potency profile across multiple HCV genotypes and key mutant strains and for its good in vitro ADME profiles and in vivo target tissue (liver) exposures across multiple animal species. X-ray crystallographic studies elucidated several key features in the binding of danoprevir to HCV NS3 protease and proved invaluable to our iterative structure-based design strategy.